An infant with a rare urea cycle disorder became the first patient to receive a personalized gene-editing therapy. His care ...

The baby boy with a rare urea cycle disorder received the bespoke therapy within a few months of birth and is doing well, ...

The baby boy received the bespoke therapy within a few months of birth and is doing well, according to a presentation at ASGCT.

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

Intranasal mRNA delivery represents a promising route for therapeutic applications, including vaccines, gene therapy, and treatments for respiratory and neurological conditions. This administration ...

One such therapy, called “grounding” or “earthing,” involves reconnecting with the Earth’s energy by standing barefoot on natural surfaces. While it may sound simple, the practice is now ...

Moderna is currently in the very early stages of testing a bird flu vaccine using the same mRNA technology that allowed for rapid development and rollout of COVID-19 vaccines. The funds from the ...

Moderna is currently in the very early stages of testing a bird flu vaccine using the same mRNA technology that allowed for rapid development and rollout of COVID-19 vaccines. The funds from the U.S.

in Chicago April 25-30 and the American Society of Gene and Cell Therapy (ASGCT) in New Orleans May 13-17. The proof-of-concept studies demonstrate that Strand’s programmable mRNA genetic circuits can ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). About a year after the FDA rejected the company's prior approval filing ...

GIZ943, also known as [177Lu] Lu-EVS459, is a radioligand therapy that targets cells that express folate receptor alpha (FRα). The spokesperson said Novartis stopped development “based on an ...

The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers. The agency cleared Abeona ...